Trem2 agonists for the stimulation of microglia and methods of identification
AssigneeThe Translational Genomics Research Institute
InventorsIsabelle Schrauwen, Matthew Huentelman, Wayne Jepsen
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of promoting phagocytosis, particularly the phagocytic activity of microglia via activation of triggering receptor expressed on myeloid cells 2 (TREM2). The present disclosure is also directed to methods of activating TREM2 in a cell, particularly a neuronal cell exhibiting an accumulation of a pathogenic protein. The present disclosure is directed to detecting an effect of a compound on the TREM2 activity as well.
Claims20
A method of activating a triggering receptor expressed on myeloid cells 2 (TREM2) in a cell, comprising contacting the cell with a compound selected from the group consisting of:
- Tyrphostin AG 538, AC1NS458, IN1040, Butein, Okanin, AGL 2263, GB19, GB16, GB20, GB17, GB18, GB21, GB22, GB27, GB44, GB42, GB2, 4,4′-Dihydroxychalcone, 3,4-Dihydroxybenzophenone, derivatives thereof, and salts thereof, wherein the amount of the compound is sufficient to activate TREM2 in the cell.
A method of detecting an effect of a compound on the triggering receptor expressed on myeloid cells 2 (TREM2) activity, comprising the steps of:
- applying the compound to the host cell, wherein the host cell expresses TREM2 and TYRO protein tyrosine kinase binding protein (TYROBP) and the host cell has a synthetic sequence comprising an NFAT-response element and a nucleotide sequence encoding a reporter;
- and
- measuring a signal emitted by the reporter in the host cell.
Dependencies are inferred from the claim text.